AUA: Prostate Cancer

Videos

“Although [whole-gland] treatments are very successful, from the oncologic perspective, our goal was to develop and test a new treatment modality in which we treat only the area with the significant cancer using focused ultrasound in the MRI gantry,” says Behfar Ehdaie, MD, MPH.

Study finds focal therapy a safe option for treating intermediate-risk prostate cancer

“I think the real driving factor in all of this is that collecting smoking status and tobacco use is hard. It's difficult to get this information out. It requires a lot of time; it requires energy; it requires infrastructure in the data and the electronic medical record,” says Richard Matulewicz, MD, MS.

Dr. Matulewicz discusses underreported smoking status in GU cancer trials

“We [found] that patients' overall [total] bowel symptoms scores were improved for those of the patients who received the active therapeutic treatment of [darolutamide] versus placebo,” says Neal D. Shore, MD, FACS.

Dr. Shore discusses effects of darolutamide on urinary and bowel symptoms 

Articles

Among the key findings was that CDK inhibition may overcome PARP resistance.

Study shines light on mechanism of olaparib resistance in prostate cancer

The latest findings for the PARP inhibitor in prostate cancer come from an analysis of the pivotal phase 3 PROfound trial presented during the 2021 AUA Annual Meeting.

Update offers clues to optimal olaparib use in prostate cancer

“These studies highlight important research in better predicting the behavior and outcomes of prostate cancer in African American men compared to men of other racial and ethnic groups,” says Brian T. McNeil, MD, MBA, FACS.

AUA 2021 studies assess racial disparities in prostate cancer

In this interview, Shore discusses findings of a study of darolutamide (Nubeqa) presented at the 2021 AUA annual meeting and their significance for patients with nonmetastatic castration-resistant prostate cancer. 

Darolutamide reduces local symptoms in patients with nmCRPC

“This device is unique in that because it's done during real-time MRI imaging while the patient is in the MRI machine, [we] can monitor the temperatures achieved by our treatment in real time and make adjustments in real time. What that means is that we're able to determine areas that will be sensitive to the treatment, both cancer and areas from a quality-of-life perspective,” says Behfar Ehdaie, MD.

Dr. Ehdaie weighs in on focal therapy with MRgFUS for GG2/3 prostate cancer

Magnetic resonance–guided focused ultrasound (MRgFUS) may be an effective alternative to radical therapy that improves outcomes for sexual function and urinary incontinence in men with intermediate-risk prostate cancer. 

MR-guided focal therapy emerges as alternative to radical therapy for intermediate-risk prostate cancer

Patients with prostate cancer have a 20% to 30% incidence of depression and anxiety; however, practicing yoga could improve their quality of life. 